Compare Sana Biotechnology Inc (SANA) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $947.48M), while Vanguard S&P 500 Growth Index Fund ETF trades at $83.87. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VOOG | |
|---|---|---|
Market Cap | $947.48M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $85.69 |
52-Week Low | $2.68 | $65.32 |
Enterprise Value | $860.73M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
VOOG trades at $84.08, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on S&P 500 growth stocks, offering exposure to large-cap leaders with a low expense ratio of 0.07% (Vanguard, 2026). Recent news highlights strong long-term performance, including over 400% total returns in the past decade (The Motley Fool, 2026-09-07).
Outlook remains positive for growth-oriented investors, supported by institutional buying and media optimism. Key risks include tech sector concentration and market volatility. Analysts favor VOOG for its cost efficiency and historical outperformance, though valuation sensitivity persists amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
